S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
NYSEAMERICAN:IBIO

iBio (IBIO) Stock Price, News & Analysis

$4.07
+0.71 (+21.13%)
(As of 11:57 AM ET)
Today's Range
$3.66
$4.78
50-Day Range
N/A
52-Week Range
$1.02
$49.00
Volume
33.00 million shs
Average Volume
3.36 million shs
Market Capitalization
$14.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

IBIO Stock Price History

IBIO Stock News Headlines

IBio In Partnership With AstralBio; Shares Up In Pre-market
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
iBio (NYSEAMERICAN:IBIO) Now Covered by StockNews.com
See More Headlines
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Today
3/27/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:IBIO
CIK
N/A
Employees
26
Year Founded
N/A

Profitability

Net Income
$-65,010,000.00
Pretax Margin
-41,546.00%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Book Value
$15.15 per share

Miscellaneous

Free Float
3,445,000
Market Cap
$11.87 million
Optionable
N/A
Beta
-3.77
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Martin B. Brenner D.V.M. (Age 53)
    Ph.D., CEO & Chief Scientific Officer
    Comp: $577.31k
  • Mr. Felipe Duran (Age 44)
    Chief Financial Officer
    Comp: $1.07M
  • Stephen Kilmer
    Investor Relations Officer
  • Mr. Marc Banjak J.D.
    General Counsel
  • Mr. Robert B. Kay (Age 84)
    Interim Secretary & Interim Treasurer
    Comp: $92.69k

IBIO Stock Analysis - Frequently Asked Questions

Are investors shorting iBio?

iBio saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 59,300 shares, a drop of 44.7% from the February 29th total of 107,200 shares. Based on an average daily volume of 99,100 shares, the short-interest ratio is presently 0.6 days. Currently, 1.7% of the shares of the company are short sold.
View iBio's Short Interest
.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings results on Friday, February, 9th. The company reported ($2.42) EPS for the quarter.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

Who are iBio's major shareholders?

iBio's stock is owned by many different retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:IBIO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners